Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...
Guggenheim downgrades Incyte on povorcitinib’s ‘somewhat underwhelming’ profile
As previously reported, Guggenheim downgraded Incyte (INCY) to Neutral from Buy and removed the firm’s previous $92 price target after the ...
Incyte Povorcitinib Studies Hit Main Goal in Hidradenitis Suppurativa
The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...
Incyte Had a Bad Week. Investors Are Used to It.
Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...
Fierce Biotech4d
Incyte posts phase 3 skin condition wins but details disappoint, sinking stock
Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...
Healio3d
New data support efficacy, safety of povorcitinib for hidradenitis suppurativa
Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results
Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.